MarginProbe 2.0 Data Collection Protocol
- Conditions
- Breast Cancer
- Registration Number
- NCT05377229
- Lead Sponsor
- Dilon Medical Technologies Ltd.
- Brief Summary
Previous clinical studies with the MarginProbe (MP) system demonstrated the MP System diagnostic accuracy for identification of cancerous/abnormal tissue at the margins (≤ 1mm) of the ex-vivo lumpectomy specimen. The current study is a prospective data collection study with the enhanced technology, the MP2.0 System and is aimed at collecting data to optimize the system algorithm/procedure and to subsequently validate the system to demonstrate non-inferiority to the MP1.x system.
In this study, MP2.0 system will be used on ex-vivo lumpectomy specimens at the Operating Room (OR). The study will collect a library of case information data using the MP2.0 system in sequential cohorts of a minimum of 50 subjects until the software and procedure are optimized. The final analysis sample size will be determined and outlined in the SAP based upon the results of the optimization stage.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 1000
- Women over 18 years of age
- Diagnosed with cancer, undergoing lumpectomy or partial mastectomy procedure
- Signed Informed Consent Form
- Undergoing re-excision procedure
- Concurrent infectious disease
- Pregnancy
- Lactation
- Previous surgery in the same site including open biopsy procedure, previous breast reduction or mastopexy in the operated breast
- Prior radiation treatment in the operated breast
- Participating in any other investigational study for either drug or device which can influence collection of valid data under this study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse Events (AEs) and Serious Adverse Events (SAEs) During the lumpectomy surgery Adverse Events (AEs) and Serious Adverse Events (SAEs)
Collect MP2.0 data in cohorts of a minimum of 50 subjects to optimize MP2.0 algorithm and procedure. During the lumpectomy surgery The cohorts will continue to be collected until a final algorithm is established and the cohort(s) can be collected with the final algorithm to determine the sensitivity and specificity to demonstrate non-inferiority to the MP1.x system.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
Logan Health Breast Center
🇺🇸Kalispell, Montana, United States
Englewood Health
🇺🇸Englewood, New Jersey, United States
Northwell Northern Westchester
🇺🇸Mount Kisco, New York, United States
Northwell Health
🇺🇸Staten Island, New York, United States
Lehigh Valley
🇺🇸Bethlehem, Pennsylvania, United States
Hadassah Medical Organization
🇮🇱Jerusalem, Israel
Health and Hospitals Corporation/Kings County
🇺🇸Brooklyn, New York, United States
Mercy Medical Center
🇺🇸Cedar Rapids, Iowa, United States
Glendale Adventist Medical Center
🇺🇸Glendale, California, United States